ARTIVION, INC. (AORT) Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Artivion, Inc. NYSE:AORT Healthcare · Medical - Devices
Prev close $20.21 Open $20.32 Now $19.71 VOL 192K $ Vol $3.88M RVOL 0.28x
Mkt Cap $961.65M
VOL 192K sh
$ Vol $3.88M
RVOL 0.28×
Press Release ⚠ 4
Artivion Reports Third Quarter 2026 Financial Results
Artivion delivered Q3 2026 revenue of $123.8 million, up 9% year-over-year on both GAAP and constant currency bases, led by 13% constant currency On-X growth and 12% stent graft growth.
Profitability deteriorated: GAAP results swung to a $(7.9) million net loss ($(0.16) per share) from $6.5 million net income a year ago, non-GAAP EPS halved to $0.08, adjusted EBITDA fell 8% to $22.5 million, and Q3 free cash flow was $(17.6) million.
Management narrowed FY2026 guidance to revenue of $484-$492 million (8-10% constant currency growth) and adjusted EBITDA of $93-$98 million, citing the ~$8 million Endospan acquisition expense.
Pipeline catalysts remain intact: U.S. AMDS implants rose sequentially post-PMA approval, the NEXUS U.S. commercial launch is on track for January 2027, and the company sees a ~$330 million annual U.S. aortic arch market opportunity.
• 3d ago AI analysis › Press Release
Artivion to Participate in Upcoming Investor Conferences
Artivion announced its management team will present at two upcoming investor conferences in November 2026.
The company presents at the Stifel 2026 Healthcare Conference on November 10 at 11:20 a.m. ET and at the 20th Annual Canaccord Genuity MedTech Forum on November 11 at 8:00 a.m. ET.
Live webcasts will be available on Artivion's investor relations website, with archives accessible for 90 days. No new financial or business information was disclosed.
• 11d ago AI analysis › Press Release
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Artivion announced it will release third quarter 2026 financial results on Thursday, November 5, 2026, after market close.
The company will host a teleconference and live webcast at 4:30 p.m. ET the same day, with Q&A hosted by Chairman, President and CEO Pat Mackin.
The release contains no results or guidance; it is a scheduling notice only.
• 17d ago AI analysis › Press Release ● Major ⚠ 3
Artivion Reports Second Quarter 2026 Financial Results
Artivion reported second quarter revenue of $125.8 million, up 11% year-over-year, driven by 18% growth in On-X mechanical heart valves and 12% growth in stent grafts.
During the quarter, the company achieved two major strategic milestones: the completion of the Endospan acquisition and the U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.
Management reaffirmed full-year 2026 guidance for revenue of $480-$496 million and adjusted EBITDA of $92-$99 million, citing confidence in the expanded aortic arch portfolio.
• 3mo ago AI analysis › Press Release
Artivion to Participate in Upcoming Investor Conferences
Artivion announced that its management team will participate in two upcoming investor conferences, the Canaccord Genuity 46th Annual Growth Conference and the Needham Virtual MedTech & Diagnostics 1x1 Conference.
The Canaccord presentation is scheduled for August 12, 2026, at 9:30 a.m. ET, with a live webcast available on the company's website.
Management will also attend the Needham conference on August 11, 2026, though no webcast will be available for this virtual event.
• 3mo ago AI analysis › Press Release
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion announced it will release second quarter 2026 financial results on Thursday, August 6, 2026, after the market closes.
A teleconference call and live webcast are scheduled for 4:30 p.m. ET on the same day to discuss the results, hosted by CEO Pat Mackin.
Investors may access the call via webcast on the company's website or by telephone, with a replay available shortly after the event.
• 3mo ago AI analysis › Press Release ● Critical
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion received FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute Debakey Type I aortic dissections, eliminating the need for institutional review board approval.
The approval is supported by data from the PERSEVERE trial, which demonstrated a 72% reduction in all-cause mortality and zero occurrence of DANE tears at 30 days compared to standard care.
This regulatory milestone allows Artivion to fully penetrate an estimated $150 million annual U.S. market and accelerates adoption of the technology.
• 4mo ago AI analysis › Press Release
Artivion to Participate in the 2026 Truist Securities MedTech Conference
Artivion will participate in the 2026 Truist Securities MedTech Conference on June 16, 2026.
The fireside chat is scheduled for 1:00 p.m. ET at the Boston Harbor Hotel.
A live webcast will be available on Artivion's investor relations website, with an archived copy accessible for 90 days.
• 4mo ago AI analysis › Press Release ● Critical
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Artivion (NYSE: AORT) has closed its acquisition of Endospan, a pioneer in endovascular solutions for complex aortic pathologies.
The deal follows the April 2026 FDA PMA approval of Endospan’s NEXUS Aortic Arch System, the first off-the-shelf endovascular solution for aortic arch disease.
The base purchase price is $175 million (less loan offsets), with up to $200 million in additional earn-out consideration tied to U.S. commercial performance over two years.
Artivion stated the acquisition completes its market-leading, three-pronged aortic arch portfolio, combining NEXUS with its existing AMDS and ARCEVO LSA products.
• 5mo ago AI analysis › Press Release ● Major
Artivion Completes Acquisition of Endospan Ltd.
Artivion has completed its acquisition of Endospan Ltd., a pioneer in endovascular repair of aortic arch disease, for an upfront net purchase price of $135 million.
The transaction was funded using a previously drawn $150 million delayed draw term loan, avoiding the need for new dilutive equity financing or additional debt issuance at closing.
This acquisition completes Artivion’s three-pronged aortic arch portfolio, combining the NEXUS system with its existing AMDS and ARCEVO LSA products to create a unique global position as the only company with a complete suite of aortic arch solutions.
• 5mo ago AI analysis › Press Release
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Artivion will release its first quarter 2026 financial results on Thursday, May 7, 2026, after the market closes.
Management will host a teleconference and live webcast at 4:30 p.m. ET to discuss the results, featuring a Q&A session led by CEO Pat Mackin.
Replays of the call will be accessible via dial-in and the company's investor relations website.
• 6mo ago AI analysis › 
